Royal London Asset Management
ACOR

Royal London Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Royal London Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-190
Closed -$604K – 562
2015
Q3 		$604K Buy
+190
New +$737K 0.01% 559
2014
Q4 		$38.3K Sell
784
-46
-6% -$197K 0.07% 291
2014
Q3 		$3.56M Hold
830
– – 0.09% 246
2014
Q2 		$2.97M Buy
830
+108
+15% +$440K 0.07% 305
2014
Q1 		$2.66M Buy
+722
New +$2.92M 0.06% 329

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal London Asset Management's ACOR Position: Q4 2015 in Review

Royal London Asset Management sold out of Acorda Therapeutics (ACOR) in Q4 2015, closing a stake of 190 shares — an estimated $604K sold.

Royal London Asset Management first reported a position in ACOR in Q1 2014 and held it in 5 quarters. The position peaked at $3.56M in Q3 2014. 186 funds tracked by Wall St. Rank hold ACOR as of Q4 2015.

  • Royal London Asset Management reported no remaining Acorda Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Royal London Asset Management sold 190 Acorda Therapeutics shares in Q4 2015, an estimated $604K.
  • Royal London Asset Management first reported a position in Acorda Therapeutics in Q1 2014 and held it in 5 quarters.
  • Royal London Asset Management's Acorda Therapeutics position peaked at $3.56M in Q3 2014.
  • 186 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2015.

Based on Royal London Asset Management's 13F filing for Q4 2015, filed 25 Feb 2016.